期刊文献+

甲磺酸去铁胺佐剂对甲型肝炎病毒抗原诱导小鼠体液免疫应答的影响 被引量:1

Effect of deferoxamine adjuvant on humoral immune response induced by hepatitis A virus antigen in mice
原文传递
导出
摘要 目的探讨甲磺酸去铁胺(deferoxamine,DFO)佐剂对甲型肝炎病毒(hepatitis A virus antigen,HAV)抗原诱导小鼠体液免疫应答的影响。方法将不同剂量的DFO(0.6、1、4、8mg)佐剂分别与HAV抗原18EU混合,免疫ICR小鼠,并设生理盐水对照组(生理盐水200 μl)、HAV抗原对照组(HAV 18 EU)、铝佐剂对照组(铝佐剂300μg+HAY抗原18EU)和复合佐剂组(HAY抗原18EU+DFO1mg+铝佐剂150 μg),均经腹部皮下多点注射,0.2ml/只,共免疫1次。分别于免疫后第4、8、12、16周,采用间接ELISA法检测小鼠血清中抗-HAV IgG水平,并进行安全性试验。结果除生理盐水对照组外,其他各组小鼠血清在各时间点均能检测到抗.HAVIgG;除DFO 0.6mg组外,抗体滴度均在第8周达峰值;不同剂量DFO组的抗体水平均明显高于HAV抗原对照组,其中DFO4mg和8mg组在8~16周时抗体水平显著高于HAV抗原对照组,且差异有统计学意义(P〈0.05),但与铝佐剂对照组比较,差异无统计学意义(P〉0.05);在8~16周时,同一时间DFO4mg、DFO8mg和复合佐剂组的抗体水平较高,并能维持较长时间,至第16周时仍能达到与铝佐剂对照组相当的水平。结论DFO佐剂能显著增强HAV抗原诱导小鼠的体液免疫应答,有望开发为一种可替代铝佐剂的新型佐剂。 Objective To investigate the effect of deferoxamine (DFO) on humoral immune response induced by hepatitis A virus (HAV) antigen in mice. Methods ICR mice were immunized with 18 EU HAV antigen combined with DFO at various dosages (0. 6, 1, 4 and 8 mg) respectively by s. c. injection in several sites at a volume of 0. 2 ml, using 200 μl of physiological saline, 18 EU HAV antigen alone and 300 μg aluminum adjuvant + 18 EU HAV antigen and complex adjuvant (18 EU HAV antigen + 1 mg DFO + 150 μg aluminum adjuvant) as controls. Serum samples were collected at weeks 4, 8, 12 and 16 after immunization, and determined for anti-HAV IgG levels by indirect ELISA. Meanwhile, safety test was performed. Results Anti-HAV IgGs were detected in sera of mice at various time points in various groups except physiological saline control group. The IgG titers in various groups except DFO 0.6 mg group reached peak values at weeks 8 after immu- nization. The anti-HAV IgG levels of mice after immunization with HAV antigen combined with DFO adjuvant at various dosages were higher, of which those in DFO 4 and 8 mg groups at weeks 8 ~ 16 were significantly higher, than that in HAV antigen control group (P 〈0.05 ), which showed no significant difference with that in aluminum adjuvant control group (P 〈0.05). The IgG levels in DFO 4 mg, DFO 8 mg and complex adjuvant control groups at the same time points at weeks 8 ~ 16 were relatively high and persistent, which were equal to that in aluminum adjuvant control group until week 16. Conclusion DFO enhanced the humoral immune response induced by HAV in mice significantly, which might be developed as a novel adjuvant instead of aluminum adjuvant.
出处 《中国生物制品学杂志》 CAS CSCD 2014年第4期472-475,共4页 Chinese Journal of Biologicals
基金 国家高技术研究发展计划(863计划"新型疫苗佐剂的研发及其应用研究"(2012AA02A406) 云南省创新团队"中国医学科学院医学生物学研究所新型疫苗佐剂应用研究省创新团队"(2011CI140)
关键词 甲磺酸去铁胺 佐剂 甲型肝炎病毒抗原 体液免疫 Deferoxamine Adjuvant Hepatitis A virus antigen Humoral immunity
  • 相关文献

参考文献4

二级参考文献35

  • 1张勇,戴瑛,张化彪,丁新生.小胶质细胞与脑出血[J].国外医学(脑血管疾病分册),2004,12(12):914-917. 被引量:1
  • 2夏前明,李福祥,全燕,李鸿雁,肖贞良,肖欣荣.低氧习服过程中肺组织一氧化氮水平及钠-钾-ATP酶活性的变化[J].中国临床康复,2005,9(11):104-106. 被引量:11
  • 3陈秀,李作孝,佘秋琼.肿瘤坏死因子-α在大鼠实验性脑出血脑损伤中的作用[J].临床神经病学杂志,2005,18(5):347-349. 被引量:7
  • 4Jiang H Luan Z Wang J Xie J.Neuroprotective effects of iron chelator Desferal on dopaminergic neurons in the substantia nigra of rats with iron-overload[J].中国生物学文摘,2006,20(10):35-35. 被引量:18
  • 5Cappellini MD,Vichinsky E,Ford JM,et al.Evaluation of deferasirox therapy in patients with transfusional iron overload who achieve serum ferritin(SF)(less than or equal to) 1000 ng/ml in long-term studies[J].Blood,2007,110:3795.
  • 6Eshel G,Barr J,Chazan S,et al.Efficacy of orally administered deferoxamine,activated charcoal,sodium bicarbonate in acute iron intoxication in rats:implications for the treatment of pediatric iron poisoning[J].Curr Therap Res,2000,61(9):648-656.
  • 7Piga A,Gaglioti C,Fogliacco E,et al.Comparative effects of deferiprone and deferiprone on survival and cardiac disease in patients with thalassemia major:retrospective analysis[J].Haematologica,2003,88(5):489-496.
  • 8Kontoghiorghes GJ,Pattichi K,Hadjigavriel M,et al.Transfusional iron overload and chelation therapy with deferoxamine and deferiprone(L1)[J].Transfusion Science,2000,23:211-223.
  • 9Gattermann N.Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload[J].Leuk Res,2007,31(Suppl 3):10-15.
  • 10Dreyfus F.The deleterious effects of iron overload in patients with myelodysplastic syndromes[J].Blood Reviews,2008,22(Suppl 2):29-34.

共引文献22

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部